Skip to main content
. 2018 Aug 23;11:5121–5132. doi: 10.2147/OTT.S167868

Figure 5.

Figure 5

In vivo anti-proliferative effects of systemic treatment with SG611-PDCD5 combined with low-dose daunorubicin.

Notes: Tumors were measured on days 2–12 after treatment. The results were expressed as mean±SD. Compared with the control group, the combined treatment group showed a significantly higher anti-proliferative effect on days 10 and 12.

Abbreviation: DNR, daunorubicin.